M Polaneczky1, M Liblanc. 1. Department of Obstetrics and Gynecology, New York Hospital--Cornell Medical Center, New York 10021, USA.
Abstract
PURPOSE: To determine Depo-Provera continuation rates and reasons for its discontinuation among adolescents. STUDY DESIGN: Medical record reviews and telephone interviews with 159 adolescents who initiated Depo-Provera use between 1 December 1992 and 31 December 1995 at two clinics in New York City. Depo-Provera continuation was measured using lifetable analysis. RESULTS: The mean age was 17.7 +/- 1.5 years, with a median of 1 pregnancy (range 0-11). Mean follow-up was 23.4 +/- 10.7 months. Depo-Provera continuation rates were 71% at 3 months, 48% at 6 months, and 27% at 12 months, and were not affected by age, race, pregnancy or contraceptive history, clinic, or foster care status. Forty-three subjects (37% of discontinuers) restarted Depo-Provera during the study period, with a mean time to restart of 8.4 months after the last Depo-Provera injection. Side effects were the main reported reason for Depo-Provera discontinuation, primarily menstrual irregularities (26%) and weight gain (18%). Seventy percent of those discontinuing Depo-Provera owing to irregular bleeding did so after only one injection. For 23%, the single reason for discontinuation was appointment noncompliance. Restart rates were lowest among those who reported irregular bleeding (15%), weight gain (9%), and hair loss (10%), and highest among those discontinuing owing to missed appointments (87%) (p < 0.05). Pregnancies occurred in 19% of Depo-Provera discontinuers. CONCLUSION: Although Depo-Provera continuation rates among adolescents are low, over a third of discontinuers may restart the method. Aggressive management of side effects and assistance with appointment follow-up may improve long-term use. High pregnancy rates warrant close follow-up after Depo-Provera discontinuation.
PURPOSE: To determine Depo-Provera continuation rates and reasons for its discontinuation among adolescents. STUDY DESIGN: Medical record reviews and telephone interviews with 159 adolescents who initiated Depo-Provera use between 1 December 1992 and 31 December 1995 at two clinics in New York City. Depo-Provera continuation was measured using lifetable analysis. RESULTS: The mean age was 17.7 +/- 1.5 years, with a median of 1 pregnancy (range 0-11). Mean follow-up was 23.4 +/- 10.7 months. Depo-Provera continuation rates were 71% at 3 months, 48% at 6 months, and 27% at 12 months, and were not affected by age, race, pregnancy or contraceptive history, clinic, or foster care status. Forty-three subjects (37% of discontinuers) restarted Depo-Provera during the study period, with a mean time to restart of 8.4 months after the last Depo-Provera injection. Side effects were the main reported reason for Depo-Provera discontinuation, primarily menstrual irregularities (26%) and weight gain (18%). Seventy percent of those discontinuing Depo-Provera owing to irregular bleeding did so after only one injection. For 23%, the single reason for discontinuation was appointment noncompliance. Restart rates were lowest among those who reported irregular bleeding (15%), weight gain (9%), and hair loss (10%), and highest among those discontinuing owing to missed appointments (87%) (p < 0.05). Pregnancies occurred in 19% of Depo-Provera discontinuers. CONCLUSION: Although Depo-Provera continuation rates among adolescents are low, over a third of discontinuers may restart the method. Aggressive management of side effects and assistance with appointment follow-up may improve long-term use. High pregnancy rates warrant close follow-up after Depo-Provera discontinuation.
Entities:
Keywords:
Adolescent Pregnancy; Adolescents; Adolescents, Female; Age Factors; Americas; Central City; Contraception; Contraception Continuation; Contraception Termination; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--side effects; Contraceptive Methods; Contraceptive Usage; Demographic Factors; Depo-provera--side effects; Developed Countries; Economic Factors; Family Planning; Fertility; Geographic Factors; Injectables; Low Income Population--women; Medroxyprogesterone Acetate--side effects; New York; North America; Northern America; Obstacles; Organization And Administration; Population; Population Characteristics; Population Dynamics; Reproductive Behavior; Research Methodology; Research Report; Retrospective Studies; Social Class; Socioeconomic Factors; Socioeconomic Status; Spatial Distribution; Studies; United States; Urban Spatial Distribution; Urbanization; Youth
Authors: Hannah L H Lange; Martha A Belury; Michelle Secic; Alicia Thomas; Andrea E Bonny Journal: J Pediatr Adolesc Gynecol Date: 2014-05-05 Impact factor: 1.814
Authors: Cara R Muñoz Buchanan; Kathy Tomaszewski; Shang-En Chung; Krishna K Upadhya; Alexandra Ramsey; Maria E Trent Journal: Clin Pediatr (Phila) Date: 2017-02-13 Impact factor: 1.168
Authors: Andrea E Bonny; Hannah L H Lange; Erinn M Hade; Bram Kaufman; Michael D Reed; Sam Mesiano Journal: Contraception Date: 2015-06-10 Impact factor: 3.375
Authors: Tina R Raine; Anne Foster-Rosales; Ushma D Upadhyay; Cherrie B Boyer; Beth A Brown; Abby Sokoloff; Cynthia C Harper Journal: Obstet Gynecol Date: 2011-02 Impact factor: 7.661
Authors: Andrea E Bonny; Hannah L H Lange; Lynette K Rogers; Dave M Gothard; Michael D Reed Journal: Contraception Date: 2014-02-01 Impact factor: 3.375
Authors: Mags E Beksinska; Immo Kleinschmidt; Jenni A Smit; Timothy M M Farley; Helen V Rees Journal: Contraception Date: 2009-03-19 Impact factor: 3.375